In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Start-Up Previews (02/2010)

Executive Summary

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "New Antibody Platforms," features profiles of arGEN-X, Crescendo Biologics, Oligasis and Open Monoclonal Technology. Plus these Start-Ups Across Health Care: BioMarker Strategies, BMEYE, Clear Catheter Systesm, Epicardial Technologies and Optibrium.

You may also be interested in...



BMEYE BV

Nexfin from BMEYE BV is a noninvasive cardiovascular monitoring system that not only checks blood pressure--heartbeat to heartbeat--but also provides physicians with cardiac output and full hemodynamics data, measured with a finger cuff connected to a wrist unit, which is linked to a monitor.

Epicardial Technologies Inc.

Epicardial Technologies Inc. is developing a technology platform designed to enable physicians to more easily perform percutaneous, catheter-based ablation of common heart rhythm abnormalities, from the inside or the outside surface of the heart, while protecting the structures surrounding the heart from serious damage or injury. The company says its products will enable electrophysiologists to do what only surgeons can currently accomplish-effectively ablate aberrant electrical signals on the heart's outside surface-without opening the chest.

arGEN-X BV

The days when drug makers could easily sign deals with front-running antibody developers are over, ended by acquisitions and exclusive arrangements for the most desirable targets. arGEN-X BV believes this is but one dynamic that will attract partners to its therapeutic antibody platform, which entails active immunization of llamas. To flaunt the diversity and potency of its "camelid" antibodies, ArGEN-X aims to raise antibodies to traditionally tough targets, such as membrane-bound proteins like GPCRs.

Related Content

Related Companies

UsernamePublicRestriction

Register

SC142523

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel